Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
COMPLETED
NCT05447078
PHASE3

Spirulina Oral Supplement for Enhancing Host Resilience to Virus Infection

Sponsor: University of Mississippi Medical Center

View on ClinicalTrials.gov

Summary

This randomized, double blind, placebo controlled study aims to establish the impact of the oral supplement, Immulina TM, on enhancing host resilience to the effects of viral influenza infection in humans.

Official title: Impact of Oral Immulina TM on Natural Killer Cell Activities and Other Biomarkers Associated With Increasing Host Immune Resilience to Upper Respiratory Viruses in Normal Human Volunteers

Key Details

Gender

All

Age Range

18 Years - Any

Study Type

INTERVENTIONAL

Enrollment

492

Start Date

2022-07-01

Completion Date

2025-12-08

Last Updated

2026-07-30

Healthy Volunteers

Yes

Interventions

DRUG

Immulina TM

Immulina TM is a highly standardized extract derived from various preparations of Spirulina, a cyanobacterium, marketed as a dietary supplement and has been utilized in several clinical studies describing its immunopotentiating properties.

DIETARY_SUPPLEMENT

Placebo

Placebo is inert powder in cellulose capsule that appears identical to Immulina TM capsules.

Locations (1)

University of Mississippi Medical Center

Jackson, Mississippi, United States